Clinical Trials Logo

Clinical Trial Summary

This is an intervention study, aiming to use high and low dose radiotherapy combined with PD-1/PD-L1 inhibitor combined with GM-CSF to observe the effect of anti-tumor immunity and long-term therapeutic response rate, and to explore a new treatment model for patients with advanced solid tumors.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05760196
Study type Interventional
Source Renmin Hospital of Wuhan University
Contact Xiangpan Li, PhD
Phone +86-027-88041911
Email rm001227@whu.edu.cn
Status Recruiting
Phase Phase 2
Start date October 1, 2022
Completion date September 30, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04635956 - Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas Phase 2
Recruiting NCT04850560 - Sequential Low-dose Decitabine With PD-1/CD28 CD19 CAR-T in Relapsed or Refractory B-cell Lymphoma Phase 1
Recruiting NCT04670978 - Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer Phase 2
Recruiting NCT05310383 - Tislelizumab and Radiotherapy for Recurrent Cervical Cancer Phase 2
Suspended NCT05503108 - Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer Phase 3
Recruiting NCT06125834 - Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy Phase 2
Recruiting NCT03892577 - Real-world Study for Patients With Advanced Hepatobiliary Tumors
Recruiting NCT04664244 - Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma Phase 2